Susquehanna International Group, LLP Vertex Pharmaceuticals Inc Put Options Transaction History

Susquehanna International Group, LLP

9 transactions

Quarter	Operation	Price Per put	puts change	puts Held
Q3 2024 Nov 14, 2024	BUY	$460.0 - $505.78 $2.71 Million - $2.98 Million	5,900 Added 2.17%	277,300 $129 Million
Q2 2024 Aug 15, 2024	SELL	$392.81 - $485.53 $37.8 Million - $46.8 Million	-96,300 Reduced 26.19%	271,400 $127 Million
Q1 2024 May 07, 2024	SELL	$407.69 - $446.08 $45.4 Million - $49.7 Million	-111,400 Reduced 23.25%	367,700 $154 Million
Q4 2023 Feb 14, 2024	BUY	$343.0 - $410.68 $38.7 Million - $46.3 Million	112,800 Added 30.79%	479,100 $195 Million
Q3 2023 Nov 14, 2023	SELL	$338.18 - $362.46 $3.45 Million - $3.7 Million	-10,200 Reduced 2.71%	366,300 $127 Million
Q2 2023 Aug 11, 2023	BUY	$314.42 - $351.91 $39.3 Million - $44 Million	125,100 Added 49.76%	376,500 $132 Million
Q1 2023 May 16, 2023	SELL	$283.23 - $323.1 $5.15 Million - $5.88 Million	-18,200 Reduced 6.75%	251,400 $79.2 Million
Q4 2022 Feb 14, 2023	SELL	$285.76 - $321.48 $18.4 Million - $20.7 Million	-64,300 Reduced 19.26%	269,600 $77.9 Million
Q3 2022 Nov 14, 2022	SELL	$273.83 - $305.53 $15.2 Million - $17 Million	-55,500 Reduced 14.25%	333,900 $96.7 Million

1,724

222M

1.58M

1.36M

Ticker VRTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 256,691,008
Market Cap $119B
Description
Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...

Get notified when there are updates to the investment portfolio of Susquehanna International Group, LLP, based on Form 13F filings with the SEC.

Stay updated on Susquehanna International Group, LLP with notifications on news.